Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prophylactic transfusion prevents strokes in children with sickle cell anemia who have abnormalities on transcranial Doppler ultrasonographic examination. However, it is not known how long transfusion should be continued in these children. METHODS: We studied children with sickle cell disease who had a high risk of stroke on the basis of a transcranial Doppler screening examination and who had received transfusions for 30 months or longer, during which time the Doppler readings became normal. The children were randomly assigned to continued transfusion or no continued transfusion. Children with severe stenotic lesions on cerebral magnetic resonance angiography were excluded. The composite primary end point was stroke or reversion to a result on Doppler examination indicative of a high risk of stroke. RESULTS: The study was stopped after 79 children of a planned enrollment of 100 underwent randomization. Among the 41 children in the transfusion-halted group, high-risk Doppler results developed in 14 and stroke in 2 others within a mean (+/-SD) of 4.5+/-2.6 months (range, 2.1 to 10.1) of the last transfusion. Neither of these events of the composite end point occurred in the 38 children who continued to receive transfusions. The average of the last two transcranial Doppler results before transfusion was started was the only predictor of the composite end point (P=0.05). CONCLUSIONS: Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease results in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke. (ClinicalTrials.gov number, NCT00006182.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the approximately 22% of children who did not achieve normalization of transcranial Doppler velocity in spite of optimal transfusion in the trial were also protected from stroke (162).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [162]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Dams, R. O. J. A., Ie, V. I. C. M. C. K., Su, L. E. H., Iles, B. E. F., Ichinsky, E. L. V., Egelow, C. H. P., Bboud, M. I. A., Allagher, D. I. G., Utlar, K., Ichols, F. E. T. N., et al. (2015) · Cited by 1,338
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
The Use of Transcranial Ultrasonography to Predict Stroke in Sickle Cell Disease
Adams, R., McKie, V., Nichols, F., Carl, E., Zhang, D.-L., McKie, K., Figueroa, R., Litaker, M., Thompson, W., & Hess, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260905 · Cited by 658
Research works printed but not linked: 2
- Ohene-Frempong K, 1998, Blood, 91, 288
- Walters MC, 2000, Blood, 95, 1918
Cited by
Items 201–300 of 665
Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging Trends
Smiers, F. J. W., Krishnamurti, L., & Lucarelli, G. (2010) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.01.003 · Cited by 32
McLaughlin, J. F., & Ballas, S. K. (2015) · Transfusion · doi:10.1111/trf.13418 · Cited by 32
Blood Transfusion in Sickle Cell Disease
Marouf, R. (2011) · Hemoglobin · doi:10.3109/03630269.2011.596984 · Cited by 32
Regulation of iron homeostasis through the erythroferrone‐hepcidin axis in sickle cell disease
Mangaonkar, A. A., Thawer, F., Son, J. J., Ajebo, G. H., Xu, H., Barrett, N. J., Wells, L., Bowman, L., Clair, B., Patel, N., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16498 · Cited by 31
Genetic Modifiers of Sickle Cell Disease
Pincez, T., Ashley‐Koch, A. E., Lettre, G., & Telen, M. J. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.06.006 · Cited by 31
Acquired and Congenital Hemolytic Anemia
Noronha, S. A. (2016) · Pediatrics in Review · doi:10.1542/pir.2015-0053 · Cited by 31
Rivera, C. P., Veneziani, A., Ware, R. E., & Platt, M. O. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216636722 · Cited by 30
Stroke in sickle cell disease and the promise of recent disease modifying agents
Runge, A. S., Brazel, D., & Pakbaz, Z. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120412 · Cited by 30
Karafin, M. S., Hendrickson, J. E., Kim, H. C., Kuliya‐Gwarzo, A., Pagano, M. B., Perumbeti, A., Shi, P. A., Tanhehco, Y. C., Webb, J. L., Wong, E. C. C., et al. (2020) · Transfusion · doi:10.1111/trf.15863 · Cited by 30
Belisário, A. R., Sales, R. R., Toledo, N. E., Muniz, M. B. D. S. R., Velloso-Rodrigues, C., Silva, C. M., & Viana, M. B. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2789-5 · Cited by 29
The past, present and future management of sickle cell retinopathy within an African context
Amissah-Arthur, K. N., & Mensah, E. (2018) · Eye · doi:10.1038/s41433-018-0162-8 · Cited by 29
Arterial Ischemic Stroke in Children
Gemmete, J. J., Davagnanam, I., Toma, A. K., Brew, S., & Ganesan, V. (2013) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2013.03.019 · Cited by 29
Sickle Cell Disease in Nigeria -----------A Review
Emechebe, G. O., Onyire, N. B., Orji, M., & Achigbu, K. (2017) · IOSR Journal of Dental and Medical Sciences · doi:10.9790/0853-1601048794 · Cited by 29
Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia
Bernaudin, F., Pondarré, C., Galambrun, C., & Thuret, I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_4 · Cited by 29
Quirolo, K. C., Bertolone, S. J., Hassell, K. L., Howard, T. H., King, K. E., Rhodes, D. K., & Bill, J. (2014) · Transfusion · doi:10.1111/trf.12891 · Cited by 29
Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries
Bhattacharya, P., Sarmah, D., Dave, K. R., Goswami, A., Watanabe, M., Wang, X., Kalia, K., Plesnila, N., Yavagal, D. R., & Alvarez, O. A. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117510 · Cited by 28
Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort
Fox, C. K., Leykina, L., Hills, N. K., Kwiatkowski, J. L., Kanter, J., Strouse, J. J., Voeks, J. H., Fullerton, H. J., Adams, R. J., & for the Post-STOP Study Group (2022) · Stroke · doi:10.1161/strokeaha.122.038651 · Cited by 28
Recent advances in improving the management of sickle cell disease
Inati, A. C. (2009) · Blood Reviews · doi:10.1016/s0268-960x(09)70004-9 · Cited by 28
Transcranial Doppler ultrasound in children with stroke and cerebrovascular disorders
LaRovere, K. L. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000282 · Cited by 28
Cure, P., Bembea, M. M., Chou, S. T., Doctor, A., Eder, A. F., Hendrickson, J. E., Josephson, C. D., Mast, A. E., Savage, W. J., Sola-Visner, M. C., et al. (2017) · Transfusion · doi:10.1111/trf.14100 · Cited by 28
Connelly‐Smith, L. S., Tanhehco, Y. C., Chhibber, V., Delaney, M., Eichbaum, Q. G., Fernandez, C. M., Joshi, S., Schwartz, J. E., & Linenberger, M. L. (2018) · Journal of Clinical Apheresis · doi:10.1002/jca.21643 · Cited by 28
Baker, C., Grant, A. M., George, M. G., Grosse, S. D., & Adamkiewicz, T. V. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25655 · Cited by 28
Hamilton, J. L., Hatef, A., ul‐haq, M. I., Nair, N., Unniappan, S., & Kizhakkedathu, J. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109880 · Cited by 28
Stanley, H. M., Friedman, D. F., Webb, J. L., & Kwiatkowski, J. L. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26017 · Cited by 28
Mazzucco, S., Diomedi, M., Qureshi, A., Sainati, L., & Padayachee, S. T. (2017) · International Journal of Stroke · doi:10.1177/1747493017706189 · Cited by 28
Belisário, A. R., Silva, C. M., Velloso‐Rodrigues, C., & Viana, M. B. (2017) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.bjhh.2017.08.008 · Cited by 28
Transfusion support in patients with sickle cell disease
Sharma, D., Ogbenna, A. A., Kassim, A. A., & Andrews, J. C. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.007 · Cited by 27
Ohemeng, A. N., & Boadu, I. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1319794 · Cited by 27
Deferasirox for managing transfusional iron overload in people with sickle cell disease
Meerpohl, J. J., Schell, L. K., Rücker, G., Motschall, E., Fleeman, N., Niemeyer, C. M., & Bassler, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007477.pub3 · Cited by 27
Matevosyan, K., Anderson, C., & Sarode, R. (2012) · Journal of Clinical Apheresis · doi:10.1002/jca.21203 · Cited by 27
Blood transfusion for preventing stroke in people with sickle cell disease
Hirst, C., & Wang, W. C. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003146 · Cited by 27
Functional and anatomical evidence of cerebral tissue hypoxia in young sickle cell anemia mice
Cahill, L. S., Gazdzinski, L. M., Tsui, A. K., Zhou, Y.-Q., Portnoy, S., Liu, E., Mazer, C. D., Hare, G. M., Kassner, A., & Sled, J. G. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16649194 · Cited by 26
Neurologic complications of sickle cell disease
Venkataraman, A., & Adams, R. J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00068-1 · Cited by 26
Trends in comorbid sickle cell disease among stroke patients
Ovbiagele, B. I., & Adams, R. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.09.023 · Cited by 26
Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov
Lebensburger, J. D., Hilliard, L., Pair, L. E., Oster, R. A., Howard, T. H., & Cutter, G. (2015) · Clinical Trials · doi:10.1177/1740774515590811 · Cited by 26
Hyacinth, H. I., Adams, R. J., Greenberg, C. S., Voeks, J. H., Hill, A., Hibbert, J. M., & Gee, B. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134193 · Cited by 26
Magalhães, N. N. S., da Paz, T. M. M., de Medeiros, R. L., Espósito, T. S., dos Santos, O. F., Ernesto, I. C., Silva, M. S., & Rodrigues, D. D. O. W. (2020) · Brazilian Journal of Health Review · doi:10.34119/bjhrv3n5-320 · Cited by 25
Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
Papizan, J. B., Porter, S. N., Sharma, A., & Pruett‐Miller, S. M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200096 · Cited by 25
Vinci, F., Tiseo, M., Colosimo, D., Calandrino, A., Ramenghi, L. A., & Biasucci, D. G. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-05388-0 · Cited by 25
Iron in sickle‐cell disease: What have we learned over the years?
Inati, A. C., Khoriaty, E., & Musallam, K. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22721 · Cited by 25
Transcranial doppler re‐screening of subjects who participated in STOP and STOP II
Adams, R. J., Lackland, D. T., Brown, L., Brown, D., Voeks, J. H., Fullerton, H. J., Kanter, J., & Kwiatkowski, J. L. (2016) · American Journal of Hematology · doi:10.1002/ajh.24551 · Cited by 25
Cerebral hemodynamic assessment and neuroimaging across the lifespan in sickle cell disease
Jordan, L. C., & DeBaun, M. R. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17701763 · Cited by 24
Accelerated 2-D Real-Time Refraction-Corrected Transcranial Ultrasound Imaging
Mozaffarzadeh, M., Verschuur, D. J., Verweij, M. D., de Jong, N., & Renaud, G. (2022) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2022.3189600 · Cited by 24
Arterial Ischemic Stroke in Children and Young Adults
Lo, W. D., & Kumar, R. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000438 · Cited by 24
Tzounakas, V. L., Valsami, S. I., Kriebardis, A. G., Papassideri, I. S., Seghatchian, J., & Antonelou, M. H. (2018) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2018.05.018 · Cited by 24
Oral Iron Chelators and the Treatment of Iron Overload in Pediatric Patients With Chronic Anemia
Vichinsky, E. P. (2008) · PEDIATRICS · doi:10.1542/peds.2007-1824 · Cited by 24
Omena, J., Rodrigues, C. D. S. C., Cardoso, J. D. D. A., Soares, A. R., Fleury, M. K., Brito, F. D. S. B., Koury, J. C., & Citelli, M. (2018) · Nutrients · doi:10.3390/nu10040498 · Cited by 23
Abdullahi, S. U., Wudil, B. J., Bello‐Manga, H., Musa, A. B., Gambo, S., Galadanci, N. A., Aminu, H., Tijjani, A., Sanusi, S. M., Tabari, M. A., et al. (2020) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2020.1810183 · Cited by 23
Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease
Zheng, Y., & Chou, S. T. (2020) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2020.10.007 · Cited by 23
Freundlich, C. L., Cervantes-Arslanian, A. M., & Dorfman, D. H. (2012) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2012.05.005 · Cited by 23
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
Estcourt, L. J., Kimber, C., Hopewell, S., Trivella, M., Doree, C. J., & Abboud, M. R. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012389.pub3 · Cited by 23
Post-transfusional iron overload in the haemoglobinopathies
Thuret, I. (2012) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2012.09.010 · Cited by 23
Stem-cell transplantation in children and adults with sickle cell disease: an update
Khoury, R. A., & Abboud, M. R. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.23 · Cited by 23
Bernaudin, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101523 · Cited by 23
Treatment and prevention of stroke in children with sickle cell disease
Mehta, S. H., & Adams, R. J. (2006) · Current Treatment Options in Neurology · doi:10.1007/s11940-006-0040-8 · Cited by 23
Application of genomics for transfusion therapy in sickle cell anemia
Chou, S. T., & Westhoff, C. M. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.006 · Cited by 22
Calvaruso, G., Vitrano, A., Maggio, R. D., Ballas, S. K., Steinberg, M. H., Rigano, P., Sacco, M., Telfer, P. T., Renda, D., Barone, R. M. E., et al. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.04.004 · Cited by 22
The challenge of clinical end points in sickle cell disease
Ataga, K. I. (2023) · Blood · doi:10.1182/blood.2023021220 · Cited by 21
Rates of strokes in Californians with sickle cell disease in the post-STOP era
Oluwole, O. B., Brunson, A. M., Adesina, O., Willen, S. M., Keegan, T. H. M., Fertrin, K. Y., & Wun, T. (2024) · Blood · doi:10.1182/blood.2023023031 · Cited by 21
Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective
Vichinsky, C. E. P., Ohene‐Frempong, K., Thein, R. C. S. L., Lobo, C. L. D. C., Inati, A. C., Thompson, A. A., Smith-Whitley, O. F. K., Kwiatkowski, J. L., Swerdlow, P. S., Porter, J. B., et al. (2010) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2010.505506 · Cited by 21
Neuroimaging in assessment of risk of stroke in children with sickle cell disease
Arkuszewski, M., Melhem, E. R., & Krejza, J. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0045-0 · Cited by 21
The management of painful crisis in sickle cell disease
Wright, J., & Ahmedzai, S. H. (2010) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e328339429a · Cited by 20
Vascular access for red blood cell exchange
Otrock, Z. K., Thibodeaux, S. R., & Jackups, R. (2018) · Transfusion · doi:10.1111/trf.14495 · Cited by 20
Mean platelet volume can predict cerebrovascular events in patients with Sickle Cell Anemia
Çelik, T., Ünal, Ş., Ekıncı, O., Özer, C., İlhan, G., Oktay, G., & Arıca, V. (2014) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.311.4104 · Cited by 20
Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering
Menaker, N. F., Halligan, K. E., Shur, N. E., Paige, J., Hickling, M., Nepo, A. G., & Weintraub, L. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000786 · Cited by 20
Colombatti, R., Jastaniah, W. A., Makani, J., & Andemariam, B. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02278-0 · Cited by 19
Alsultan, A. S., Jastaniah, W. A., Alafghani, S., Albagshi, M. H., Naserullah, Z. A., AlSuliman, A. M., & Alabdulaali, M. K. (2016) · Pediatric Transplantation · doi:10.1111/petr.12767 · Cited by 19
Advances in new drug therapies for the management of sickle cell disease
Ataga, K. I., & Desai, P. C. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1471983 · Cited by 19
Aguilar‐Salinas, P., Hayward, K., Santos, R., Agarwal, V., Sauvageau, E. A., Hanel, R. A., & Aldana, P. R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.11.157 · Cited by 19
Advances in neuroimaging to improve care in sickle cell disease
Jordan, L. C., DeBaun, M. R., & Donahue, M. J. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30490-7 · Cited by 18
Brain health equity and the influence of social determinants across the life cycle
Bach, A., Peeler, M., Caunca, M. R., Olusanya, B. O., Rosendale, N., & Gano, D. L. (2024) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2024.101553 · Cited by 18
Jordan, L. C., Williams, D. O. R., Rodeghier, M., Greene, B. C., Ponisio, M. R., Casella, J. F., McKinstry, R. C., Noetzel, M. J., Kirkham, F. J., Meier, E. R., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25085 · Cited by 18
Sickle cell disease: looking back but towards the future
Cançado, R. D. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120041 · Cited by 18
Vichinsky, E. P., & Ohene‐Frempong, K. (2010) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2010.505497 · Cited by 18
Raphael, J. L., Kavanagh, P. L., Wang, C.-H. J., Mueller, B. U., & ZUCKERMAN, B. S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23059 · Cited by 17
Role of TCD in sickle cell disease: A review
Zétola, V. D. H. F. (2012) · Perspectives in Medicine · doi:10.1016/j.permed.2012.03.016 · Cited by 17
Transfusion Therapy in Children With Sickle Cell Disease
Inati, A. C., Mansour, A. G., Sabbouh, T. M., Amhez, G., Hachem, A. A., & Abbas, H. A. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000645 · Cited by 17
Schlenz, A. M., Phillips, S. M., Mueller, M., Melvin, C. L., Adams, R. J., Kanter, J., & On Behalf of the DISPLACE Investigators (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28172 · Cited by 17
Verlhac, S., Gabor, F., Paillard, C., Chateil, J., Jubert, C., Petras, M., Grévent, D., Brousse, V. A. M., Petit, P., Thuret, I., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17178 · Cited by 17
Phillips, S. M., Schlenz, A. M., Mueller, M., Melvin, C. L., Adams, R. J., & Kanter, J. (2021) · Implementation Science Communications · doi:10.1186/s43058-021-00192-z · Cited by 17
Improving Outcomes in Children with Sickle Cell Disease: Treatment Considerations and Strategies
Amid, A., & Odame, I. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0074-4 · Cited by 17
Pulmonary hypertension in sickle cell disease: diagnosis and management
Ataga, K. I., & Klings, E. S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.425 · Cited by 17
Cerebrovascular complications in children with sickle cell disease
de Montalembert, M., & Wang, W. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59565-2.00064-2 · Cited by 17
Iron chelation therapy for patients with sickle cell disease and iron overload
Inati, A. C., Khoriaty, E., Musallam, K. M., & Taher, A. T. (2010) · American Journal of Hematology · doi:10.1002/ajh.21806 · Cited by 17
Sheehan, V., Hansbury, E. N., Smeltzer, M. P., Fortner, G., McCarville, M. B., & Aygün, B. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24569 · Cited by 17
Transfusion practices for patients with sickle cell disease at a major academic medical center
Afenyi‐Annan, A., & Bandarenko, N. (2006) · Immunohematology · doi:10.21307/immunohematology-2019-364 · Cited by 17
Vascular Diseases of the Nervous System
Biller, J., Love, B. B., & Schneck, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7506-7525-3.50069-8 · Cited by 17
Current state of gene therapy in sickle cell disease
Tang, M. S., & Shan, H. (2024) · Vox Sanguinis · doi:10.1111/vox.13612 · Cited by 16
Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease
Jordan, L. C., King, A. A., Kanter, J., Lebensburger, J. D., Ford, A. L., Varughese, T. E., Garrett, L. M., Mullis, L., Saint‐Jean, L., Davis, S. M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033278 · Cited by 16
Loggetto, S. R., Veríssimo, M. P. D. A., Darrigo, L. G., Simões, R. S., Bernardo, W. M., & Braga, J. A. P. (2021) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2021.09.013 · Cited by 16
Savage, W. J., Reddoch, S., Wolfe, J. L., & Casella, J. F. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31829d470d · Cited by 16
Current Understanding in the Management of Sickle Cell Disease
Inati, A. C., Chabtini, L., Mounayar, M., & Taher, A. T. (2009) · Hemoglobin · doi:10.3109/03630260903347682 · Cited by 16
Santiago, R. P., Vieira, C., Adanho, C. S. A., Santana, S. S., da Guarda, C. C., Figueiredo, C. V. B., Fiuza, L. M., Pitanga, T. N., Ferreira, J. R. D., Aleluia, M. M., et al. (2017) · Disease Markers · doi:10.1155/2017/6359871 · Cited by 16
Dokékias, A. E., Ossini, L. N., Tsiba, F. G. A., Malanda, F., Koko, I., & de Montalembert, M. (2009) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2009.01.003 · Cited by 16
Dunbar, L. N., Brown, L., Rivera, D. R. R., Hartzema, A. G., & Lottenberg, R. (2012) · ISRN Hematology · doi:10.5402/2012/524513 · Cited by 16
Plasma Glial Fibrillary Acidic Protein Levels in a Child with Sickle Cell Disease and Stroke
Savage, W. J., Everett, A. D., & Casella, J. F. (2010) · Acta Haematologica · doi:10.1159/000321791 · Cited by 16
Canellas, C. G. L., de Carvalho, S. M. F., Anjos, M. J., & Lopes, R. T. (2012) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2011.12.028 · Cited by 16
Chevret, S., Verlhac, S., Ducros-Miralles, E., Dalle, J., de Latour, R. P., de Montalembert, M., Benkerrou, M., Pondarré, C., Thuret, I., Guitton, C., et al. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.08.008 · Cited by 16
Day, M. E., Rodeghier, M., & DeBaun, M. R. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27352 · Cited by 16
Neurovascular Manifestations of Sickle Cell Disease
Zedde, M., Quaresima, M., Capodanno, I., Grisendi, I., Assenza, F., Napoli, M., Moratti, C., Pavone, C., Bonacini, L., Cecco, G. D., et al. (2024) · Hemato · doi:10.3390/hemato5030023 · Cited by 16
Metadata
- Authors
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
- Affiliations
- Augusta University (US)
- Corresponding author
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-29
- Volume
- 353
- Issue
- 26
- Pages
- 2769-2778
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1498156640
- Cited by
- 635
- References
- 27
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 31 · 2023: 22 · 2022: 29 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 35 · 2017: 37 · 2016: 43 · 2015: 25 · 2014: 32 · 2013: 32 · 2012: 45
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01HL052193, U01HL052016)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- sickle cell disease, stroke prevention, prophylactic transfusion, transcranial Doppler screening, cerebral blood flow velocity, children
- MeSH terms
- Adolescent, Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Transfusion, Brain, Child, Female, Humans, Magnetic Resonance Imaging, Male, Risk, Chelation Therapy, Ultrasonography, Doppler, Transcranial, Stroke, Middle Cerebral Artery, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.